InvestorsHub Logo
Followers 4
Posts 171
Boards Moderated 0
Alias Born 03/02/2015

Re: None

Monday, 04/19/2021 11:42:17 AM

Monday, April 19, 2021 11:42:17 AM

Post# of 861
OTLK COMPANY HIGHLIGHTS
• Lead product candidate ONS-5010 / LYTENAVATM has potential to be first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications 24
• Potential FDA Approval in 2022
• Targeting $13.1 Billion Global Ophthalmic Anti-VEGF Market1
• Potential for 12 Years of Market Exclusivity • Management Team with Extensive Clinical/Regulatory Ophthalmology & Drug Development Experience
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OTLK News